<DOC>
	<DOCNO>NCT00873197</DOCNO>
	<brief_summary>This study design investigate pharmacokinetic safety profile co-administration intravenous ( IV ) transdermal granisetron , well characterise pharmacokinetics multiple transdermal dosing .</brief_summary>
	<brief_title>PK , Tolerability Safety co-Administration Sancuso® ( Transdermal Granisetron ) IV Granisetron</brief_title>
	<detailed_description>Sancuso® design provide antiemetic prophylaxis chemotherapy 5 day duration . In exceptional clinical situation patch apply appropriate time ( i.e . 24-48 hour pre-chemotherapy ) , clinician might use single IV dose granisetron provide prophylaxis granisetron patch reach therapeutic plasma concentration . Most chemotherapeutics dose single day , 2- 3-week interval dos ; however , several regimen administer 5 day others give frequency ( e.g . every 5 day ) . Thus , one patch may require provide continuous antiemetic prophylaxis . Characterisation pharmacokinetics multiple transdermal dose offer useful information clinician treat patient latter type regimen .</detailed_description>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Healthy male female Caucasian subject Aged 18 70 year , inclusive , screen BMI 20.0 29.9 kg/m² , inclusive . Must demonstrate understanding purpose risk study Must agree follow restriction schedule study procedure Current previous disease , disorder , allergy condition could affect study conduct laboratory assessment , present undue risk study medication procedure . Physical examination screen investigation result indicate subject unfit study . Scarring upper arm . Positive virology , urine drug abuse pregnancy test result ( female childbearing potential ) . Recent use prescribe counter medication . Participation clinical study loss ≥ 400 mL blood ( e.g . blood donor ) within previous 60 day . Average weekly alcohol consumption great 21 unit ( male ) 14 unit ( female ) , habitually smoke ≥ 5 cigarette equivalent tobacco per day within 6 month first study drug administration . Lactating female subject female subject childbearing potential willing use acceptable form contraception 90 day study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Co-administration transdermal intravenous granisetron</keyword>
	<keyword>Granisetron</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Pharmacokinetic profile</keyword>
	<keyword>Sancuso® patch</keyword>
	<keyword>Transdermal</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>